Efficacy and applicability of topical cannabidiol-based treatment in psoriasis patient, randomized, placebo, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210529001

Enrollment

Registered

2021-05-29

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plaque type psoriasis patients with mild severity Psoriasis, cannabis, cannabinoid, cannabidiol, marijuana

Interventions

CBD ointment,Placebo

Active Comparator Drug,Placebo Comparator Drug

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. male/female 18-70 years 2. plaque type psoriasis, mild severity 3.able to comply with study protocol 4. willingly inform consent

Exclusion criteria

Exclusion criteria: 1. unable to stop previous treatment (washout period; systemic treatment 4 weeks, topical treatment 2 weeks). 2. abnormal liver or renal function 3. psychological disorder 4. Pregnant or lactating women 5. allergic to study product.

Design outcomes

Primary

Measure	Time frame
PASI (baseline, week 2, 4, 8, 12) PASI	—

Secondary

Measure	Time frame
Side effects week 2, 4, 8, 12 Side effects	—

Countries

Thailand

Contacts

Public ContactPravit Asawanonda

Chulalongkorn University

fibrosis@gmail.com0818129393

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026